Alzheimer's Drug Discovery Foundation
VC Fund
New York, United States
Alzheimer's Drug Discovery Foundation is a VC fund in New York focused on Biotechnology and Health Care. The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity solely dedicated to finding effective drugs for Alzheimer’s disease. Our pioneering biomedical venture philanthropy approach allows us to invest in the most promising drug discovery and development programs around the world in both academic institutions and biopharmaceutical companies. Since our founding in 1998, the ADDF has invested nearly $100 million to support over 500 programs across 18 countries.
- Total investments:
- 57
- Last investment:
- Lead investor:
- 74%
Last updated:
For AI agents: llms.txt
Industries Alzheimer's Drug Discovery Foundation invests in
Stages Alzheimer's Drug Discovery Foundation invests in
Countries Alzheimer's Drug Discovery Foundation invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Grant
- $250k–$5.8M
- Series A
- $2.1M–$85M
- Series B
- $6M–$73M
Investment Focus
Industry
- Biotechnology 33 (58%)
- Health Care 23 (40%)
- Medical 15 (26%)
- Health Diagnostics 13 (23%)
- Therapeutics 12 (21%)
Stage
- Grant 25 (44%)
- Series A 9 (16%)
- Series B 5 (9%)
- Venture - Series Unknown 5 (9%)
- Seed 3 (5%)
Country
- United States 29 (51%)
- Canada 3 (5%)
- Spain 2 (4%)
- United Kingdom 2 (4%)
- Sweden 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Howard Fillit
Co-Founder and Chief Science Officer
|
Co-Founder and Chief Science Officer | Total investments: 14 | Find email | |
Leonard Lauder
Co-Chairman & Co-Founder
|
Co-Chairman & Co-Founder | Total investments: 0 | Find email | |
Martin Tolar
Business Advisory Board & Scientific Review Board
|
Business Advisory Board & Scientific Review Board | Total investments: 0 | Find email | |
Meriel Owen
Director
|
Director | Total investments: 1 | Find email | |
|
Ronald S. Lauder
Co-Chairman and Co-Founder
|
Co-Chairman and Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugscurrently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. | $4M / Sep 22, 2026 | ||
| AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK DementiaResearch Institute. | Grant / Mar 31, 2026 | ||
| MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated.Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs. | $5M / Grant / Mar 10, 2026 | ||
Transposon Therapeutics
|
Transposon Therapeutics operates as a pharmaceutical company based in Westport, Connecticut. It specializes in developing therapeutics for debilitating and life-threatening diseases | $5M / Grant / Jul 09, 2025 | |
| Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predictswhether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health. | $250K / Grant / Jul 08, 2025 | ||
| Life Molecular Imaging is a heal diagnostic center that provides neuroimaging and cardiovascular imaging services. | $2.2M / Grant / May 14, 2025 | ||
| Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California. | $10M / Grant / Jan 08, 2025 | ||
| University of Gothenburg is a school in Gothenburg. | $1.2M / Grant / Nov 14, 2024 | ||
| GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark. | Venture - Series Unknown / Oct 29, 2024 | ||
| C2N Diagnostics is a specialty diagnostics company focused on providing laboratory services and products in brain health with innovative technologies. The C2N Diagnostics PrecivityAD Test helps physicians determine the presence of amyloid plaques in the brain, which is crucial for Alzheimer's diagnosis. C2N is known for its high-performanceblood biomarkers aimed at early diagnosis and therapeutic discovery related to brain health conditions. | $22M / Grant / Sep 25, 2024 | ||
| See all 57 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Alzheimer's Drug Discovery Foundation invest in?
Alzheimer's Drug Discovery Foundation invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Series A stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Alzheimer's Drug Discovery Foundation invest in?
Alzheimer's Drug Discovery Foundation typically joins rounds of $250k–$5.8M at Grant, $2.1M–$85M at Series A and $6M–$73M at Series B. These are whole funding-round sizes, not Alzheimer's Drug Discovery Foundation's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Alzheimer's Drug Discovery Foundation took part in.
How do I contact Alzheimer's Drug Discovery Foundation?
Public channels for Alzheimer's Drug Discovery Foundation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alzheimer's Drug Discovery Foundation?
The team at Alzheimer's Drug Discovery Foundation includes Howard Fillit (Co-Founder and Chief Science Officer), Leonard Lauder (Co-Chairman & Co-Founder) and Martin Tolar (Business Advisory Board & Scientific Review Board). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
